NO993779D0 - Fremgangsmåte for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel - Google Patents

Fremgangsmåte for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel

Info

Publication number
NO993779D0
NO993779D0 NO993779A NO993779A NO993779D0 NO 993779 D0 NO993779 D0 NO 993779D0 NO 993779 A NO993779 A NO 993779A NO 993779 A NO993779 A NO 993779A NO 993779 D0 NO993779 D0 NO 993779D0
Authority
NO
Norway
Prior art keywords
solvent
crystallizing
reverse transcriptase
transcriptase inhibitor
crystallising
Prior art date
Application number
NO993779A
Other languages
English (en)
Other versions
NO320128B1 (no
NO993779L (no
Inventor
William Clarke
Louis S Crocker
Ii Joseph L Kukura
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993779(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9706046.1A external-priority patent/GB9706046D0/en
Priority claimed from GBGB9709348.8A external-priority patent/GB9709348D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO993779D0 publication Critical patent/NO993779D0/no
Publication of NO993779L publication Critical patent/NO993779L/no
Publication of NO320128B1 publication Critical patent/NO320128B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993779A 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel NO320128B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3738597P 1997-02-05 1997-02-05
GBGB9706046.1A GB9706046D0 (en) 1997-03-24 1997-03-24 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US4280797P 1997-04-08 1997-04-08
GBGB9709348.8A GB9709348D0 (en) 1997-05-07 1997-05-07 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
PCT/US1998/001999 WO1998033782A1 (en) 1997-02-05 1998-02-02 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Publications (3)

Publication Number Publication Date
NO993779D0 true NO993779D0 (no) 1999-08-04
NO993779L NO993779L (no) 1999-10-05
NO320128B1 NO320128B1 (no) 2005-10-31

Family

ID=27451618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993779A NO320128B1 (no) 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel

Country Status (18)

Country Link
EP (1) EP0975609B1 (no)
JP (6) JP3418626B2 (no)
KR (1) KR100573192B1 (no)
CN (2) CN1073991C (no)
AT (1) ATE486065T1 (no)
AU (1) AU738545C (no)
CA (1) CA2279198C (no)
CZ (2) CZ304186B6 (no)
DE (1) DE69841972D1 (no)
EA (1) EA001805B1 (no)
EE (1) EE03827B1 (no)
HU (1) HU229087B1 (no)
IL (1) IL130715A (no)
NO (1) NO320128B1 (no)
NZ (1) NZ336510A (no)
PL (1) PL197740B1 (no)
SK (1) SK284935B6 (no)
WO (1) WO1998033782A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304186B6 (cs) * 1997-02-05 2013-12-11 Merck Sharp & Dohme Corp. Krystalická forma I inhibitoru na bázi benzoxazinu a zpusob její výroby
AR011731A1 (es) * 1997-05-16 2000-08-30 Merck & Co Inc Un proceso de reaccion de adicion enantioselectiva eficiente utilizando un reactivo de organozinc.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009087679A2 (en) * 2007-12-24 2009-07-16 Matrix Laboratories Limited Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
EP2367804B1 (en) 2008-12-22 2013-11-06 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN114195761B (zh) * 2021-12-23 2023-04-14 浙江普洛家园药业有限公司 一种高纯度西他沙星3/2水合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
CZ304186B6 (cs) * 1997-02-05 2013-12-11 Merck Sharp & Dohme Corp. Krystalická forma I inhibitoru na bázi benzoxazinu a zpusob její výroby
JP2001519810A (ja) * 1997-04-07 2001-10-23 デュポン ファーマシューティカルズ カンパニー 新規中間体を経由するベンゾオキサジノン類の不斉合成

Also Published As

Publication number Publication date
WO1998033782A1 (en) 1998-08-06
EP0975609B1 (en) 2010-10-27
ATE486065T1 (de) 2010-11-15
SK105599A3 (en) 2000-05-16
EE03827B1 (et) 2002-08-15
CN1073991C (zh) 2001-10-31
CZ304186B6 (cs) 2013-12-11
NO320128B1 (no) 2005-10-31
JP2011006472A (ja) 2011-01-13
CZ297535B6 (cs) 2007-01-03
CA2279198A1 (en) 1998-08-06
IL130715A (en) 2003-07-31
AU6263298A (en) 1998-08-25
JP2017061575A (ja) 2017-03-30
JP2003040874A (ja) 2003-02-13
JP6126172B2 (ja) 2017-05-10
CA2279198C (en) 2009-04-14
IL130715A0 (en) 2000-06-01
JP3418626B2 (ja) 2003-06-23
SK284935B6 (sk) 2006-02-02
AU738545C (en) 2004-06-17
HUP0001313A2 (hu) 2000-10-28
JP5295190B2 (ja) 2013-09-18
EE9900341A (et) 2000-02-15
JP2015205914A (ja) 2015-11-19
AU738545B2 (en) 2001-09-20
CN1191242C (zh) 2005-03-02
DE69841972D1 (de) 2010-12-09
EP0975609A4 (en) 2001-02-21
NZ336510A (en) 2001-04-27
EA001805B1 (ru) 2001-08-27
CZ276599A3 (cs) 2000-02-16
KR100573192B1 (ko) 2006-04-24
CN1246113A (zh) 2000-03-01
KR20000070735A (ko) 2000-11-25
HU229087B1 (en) 2013-07-29
NO993779L (no) 1999-10-05
PL334478A1 (en) 2000-02-28
EP0975609A1 (en) 2000-02-02
EA199900720A1 (ru) 2000-04-24
PL197740B1 (pl) 2008-04-30
CN1385425A (zh) 2002-12-18
JP2000507972A (ja) 2000-06-27
JP2013139484A (ja) 2013-07-18
HUP0001313A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
NO993779D0 (no) Fremgangsmåte for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel
TW365025B (en) Manufacturing method for gallium nitride crystal
NO20010231L (no) FremgangsmÕte til kjemisk rensing og løsningsmiddel
DE60009326D1 (de) Verfahren zur herstellung von silicoaluminophosphat-molekularsieben
KR870008379A (ko) 반도체 웨이퍼상에 포토레지스트 박리방법
ATE364060T1 (de) Mikroporöse materialien und verfahren zu ihrer herstellung
DE69627320D1 (de) Verfahren zur herstellung von mikropartikeln auf industrieller basis
GT199900100A (es) Metodo y aparato para recolectar datos de tiempo de paralizacion y equipo de fabricacion.
DE69112379D1 (de) Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen.
AR004834A1 (es) Procedimiento de la manufactura de (5-metoxi-2[[(4-metoxi-3,5-dimetil-2- piridinil)-metil]-sulfinil]-1h-bencimidazol (omeprazol)
ATE263145T1 (de) Verfahren zur herstellung von n-carbamat- geschütztem beta-aminoepoxid und beta- aminoalkohol
EP1134016A3 (en) Method and apparatus for recovering volatile organic compounds from exhaust gas
DK0689579T3 (da) Fremgangsmåde til ekstraktion af sphingomyelin
CA2319788A1 (en) A method of modifying a crystalline molecular sieve material
ES2182047T3 (es) Metodo de recuperacion de acido tereftalico y etilenglicol a partir de residuos de poli(tereftalato de etileno).
DK155947C (da) I det vaesentlige rene, vandfrie eller hydratiserede salte af l-aspartyl-d-aminosyre-dipeptid-amider med aromatiske sulfonsyrer og fremgangsmaade til fremstilling deraf
DE60024821D1 (de) Verfahren zur reinigung von aldehydverunreinigungen
DK1124812T3 (da) Fremgangsmåde til epoxidering af olefiner
KR100740474B1 (ko) 기판을 처리하는 장치 및 방법
BR0204562A (pt) Método de controle para transmissão automática de veìculos motorizados
DE69901792D1 (de) Verfahren zur herstellung von 2-acetylthio-3-phenyl-propionsäure und deren salzen
US7393760B2 (en) Method for dicing glass substrate
KR940001553B1 (ko) 마스크관리시스템
BR9813595A (pt) Cristal misto, processo para produzir o mesmo, e, adoçante
JPS59123944A (ja) プログラム間同期方式

Legal Events

Date Code Title Description
MK1K Patent expired